$INTS News

Last published 1d ago

1d agoGOOGL HCA HCC NWH+20Google Cloud Launches Gemini for HealthcareGoogle Cloud Press Corner
6d agoINTSINTENSITY THERAPEUTICS, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1w agoINTSIntensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026PR NewswireCompany to hold a conference call at 8AM ET on November 5, 2026 to review results and provide a corporate updateSHELTON, Conn., Oct. 30, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the
2w agoINTSIntensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) MeetingPR NewswirePathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%) in the INT230-6 plus standard-of-care cohortNo invasive breast cancer
2mo agoINTSIntensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
3mo agoNTHI TNGX INTSNeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight FloatGlobeNewswireDENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock trading near
3mo agoINTSIntensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatePR NewswireInitiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026Patient treatment restarted in the presurgical triple
3mo agoINTSIntensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026PR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
3mo agoINTSIntensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)PR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
4mo agoINTSIntensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6PR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
6mo agoINTSIntensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical AwardPR NewswireIntensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and ...
6mo agoINTSIntensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
7mo agoINTSIntensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare InnovationPR NewswireIntensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and ...
7mo agoINTSIntensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate UpdatePR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
7mo agoINTSIntensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the USPR NewswireIntensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and ...
8mo agoINTSIntensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 StudyPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
8mo agoINTSIntensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price RequirementPR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
9mo agoINTSIntensity Therapeutics Announces Reverse Stock SplitPR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
10mo agoINTSIntensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic PrioritiesPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
11mo agoINTSIntensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer SymposiumPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
11mo agoINTSIntensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price RequirementPR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
11mo agoINTSIntensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer SymposiumPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common StockPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science JournalPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study UpdatePR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity RequirementPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025PR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoONCY CLRB INTS ARAY+1Oncology Innovation Just Hit a Turning Point -- Here's What to WatchPR NewswireUSA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline....
1y agoINTSIntensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)PR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoONCY IMRX GRAL INTS+1With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in OncologyPR NewswireUSA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor ...
1y agoINTSIntensity Therapeutics, Inc. Announces Pricing of Public OfferingPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. Announces Proposed Public Offering of Common StockPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 StudyPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual MeetingPR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the HorizonPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in FrancePR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. Announces $2.35 Million Public OfferingPR NewswireIntensity Therapeutics, Inc. (NASDAQ: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate UpdatePR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSDrug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic ReviewPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6PR NewswireIntensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)PR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private PlacementPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)PR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and...
1y agoINTSIntensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatePR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...
2y agoINTSIntensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) MeetingPR NewswireIntensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and...
2y agoINTSIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)PR NewswireIntensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...